Expertise in
20
conditions

Dr. Adam L. Boxer

Neurology
University Of California San Francisco
2330 Post St, 
San Francisco, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
20
conditions
University Of California San Francisco
2330 Post St, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adam Boxer is a Neurologist in San Francisco, California. Dr. Boxer is highly rated in 20 conditions, according to our data. His top areas of expertise are Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Corticobasal Degeneration.

His clinical research consists of co-authoring 322 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CA
Hospital Affiliations
Ucsf Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UNIVERSITY OF CALIFORNIA SAN FRANCISCO
2330 Post St, San Francisco, CA 94115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Enrollment Status: Recruiting
Publish Date: February 13, 2025
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enrollment Status: Recruiting
Publish Date: February 28, 2024
A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease
A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug
Study Drug: Salsalate
Study Phase: Phase 1
The Four-Repeat Tauopathy Neuroimaging Initiative
The Four-Repeat Tauopathy Neuroimaging Initiative
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Other
Remote Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)
Remote Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration
Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2024
Intervention Type: Other
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drug: Solanezumab
Study Phase: Phase 3
A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drug: Syntocinon
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2
Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2
Enrollment Status: Completed
Publish Date: May 21, 2021
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: April 01, 2021
Intervention Type: Drug
Study Phase: Phase 1
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: August 11, 2020
Intervention Type: Biological
Study Phase: Phase 1
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003
Enrollment Status: Terminated
Publish Date: May 18, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy Syndromes
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy Syndromes
Enrollment Status: Terminated
Publish Date: December 19, 2019
Intervention Type: Other, Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: September 04, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 16 Less Clinical Trials

318 Total Publications

Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.
Development and validation of a harmonized memory score for multicenter Alzheimer's disease and related dementia research.
Journal: medRxiv : the preprint server for health sciences
Published: April 16, 2025
Similar Doctors
Expertise in
22
conditions
Dr. John F. De Groot
Neurology
Expertise in
22
conditions
Dr. John F. De Groot
Neurology

Ucsf Medical Group Business Services

521 Parnassus Ave, 
San Francisco, CA 
 (1.8 mi)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John De Groot is a Neurologist in San Francisco, California. Dr. De Groot is highly rated in 22 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

Expertise in
17
conditions
Dr. Howard J. Rosen
Neurology
Expertise in
17
conditions
Dr. Howard J. Rosen
Neurology

University Of California San Francisco

2330 Post St, 
San Francisco, CA 
 (0.1 mi)
415-476-4029
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Howard Rosen is a Neurologist in San Francisco, California. Dr. Rosen is highly rated in 17 conditions, according to our data. His top areas of expertise are Frontotemporal Dementia, Dementia, Primary Progressive Aphasia, and Corticobasal Degeneration.

Expertise in
20
conditions
Dr. William W. Seeley
Neurology
Expertise in
20
conditions
Dr. William W. Seeley
Neurology

University Of California San Francisco

400 Parnassus Ave, Mcb300, 
San Francisco, CA 
 (1.7 mi)
415-476-1000
Languages Spoken:
English
See accepted insurances

William Seeley is a Neurologist in San Francisco, California. Dr. Seeley is highly rated in 20 conditions, according to our data. His top areas of expertise are Frontotemporal Dementia, Dementia, Primary Progressive Aphasia, and Progressive Supranuclear Palsy Atypical.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boxer's expertise for a condition
ConditionClose
View All 11 Elite Conditions
View All 7 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile